Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

WIN 2012 /
Building international collaborations and the WINTHER trial

28th - 29th Jun 2012

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 06.07.12
Views: 3241

Dr Oliver Bogler – MD Anderson Cancer Center, Houston, USA

Dr Oliver Bogler talks to ecancer at the 2012 WIN Symposium in Paris about the WIN Consortium and clinical trials in biomarker research.


The WIN Consortium was founded in a joint effort between Dr John Mendelsohn of MD Anderson Cancer Center and Prof Alexander Eggermont of Institute Gustave Roussy and focuses on building international collaborations for further research into translational and personalised medicine.


Dr Bogler also discuses early phase clinical trials on biomarker research, with focus on the WINTHER trial, or WIN therapeutics. The trial aims to analyse the molecular characteristics of tumours and identify patient profiles; ultimately with a goal of using a variety of approaches to improve the lives of 200 patients, 50 from each participating centre. Also, noted is the Universal Biomarker project, a large-scale characterisation of tumours and attracting more centres to the WIN Consortium.


Filming Supported by Amgen

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation